VivoSeq
Oncology

Gastric Neoplasms

7

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Gastric Neoplasms is an early-stage landscape with 7 programs across 5 companies. The most active players are Jazz Pharmaceuticals, BeiGene, Teva. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 3BeiGene logo

BeiGene

1 program

Phase 3Teva logo

Teva

1 program

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 37

Zanidatamab

Jazz Pharmaceuticals

Tislelizumab

BeiGene

Trastuzumab

Organon and Co

Capecitabine

Engelhard Arzneimittel GmbH & Co.KG

Oxaliplatin

Teva

Approved
No programs

Analysis

Modality Breakdown

6programs
Small molecule350%
Monoclonal antibody350%

Modality classified for 86% of 7 pipeline programs.

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Active, not recruiting·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 3·NCT05152147·920 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)